Discounted Cash Flow (DCF) Analysis Levered

Forward Pharma A/S (FWP)

$2.81

0.00 (0.00%)
All numbers are in Millions, Currency in USD

Free Cash Flow

Year
A/P
2017
Actual
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue 1,250---------
Revenue (%)
Operating Cash Flow 939.95---------
Operating Cash Flow (%)
Capital Expenditure -0---------
Capital Expenditure (%)
Free Cash Flow 939.94---------

Weighted Average Cost Of Capital

Share price $ 2.81
Beta 1.381
Diluted Shares Outstanding 6.98
Cost of Debt
Tax Rate 0.00
After-tax Cost of Debt -%
Risk-Free Rate
Market Risk Premium
Cost of Equity 10.118
Total Debt -
Total Equity 19.62
Total Capital -
Debt Weighting -
Equity Weighting -
Wacc

Build Up Free Cash Flow

Year
A/P
2017
Actual
2018
Projected
2019
Projected
2020
Projected
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue 1,250---------
Operating Cash Flow 939.95---------
Capital Expenditure -0---------
Free Cash Flow 939.94---------
WACC
PV LFCF ---------
SUM PV LFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) -
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -70.77
Equity Value -
Shares Outstanding 6.98
Equity Value Per Share -